RPhLink.com  The Pharmaceutical Care Network!

RPhLink.com  A Great Link for the IPhBOs (Independent Pharmacy Business Owners) RPhLink.com The Pharmaceutical care Network! 10/01/2004 Acarda's Acquisition of Zanaflex From Elan From Acorda Acorda Therapeutics is pleased to announce the acquisition of Zanaflex (tizanidine HCL) Tablets from Elan Pharmaceuticals. Both Zanaflex strengths are included in this acquisition as follows: Elan NDC#               Strength & Package Size 59075-0592-15          2mg., 150's. 59075-0594-15          4 mg., 150's Zanaflex will continue to be available exclusively through the traditional wholesaler distribution system and wholesalers are shipping the product under the Acorda name. For the near future, Acorda will be distributing existing Elan labeled inventories and wholesalers have been advised to set their inventory systems to link Zanaflex to Acorda to accommodate pharmacy orders. The product package size, NDC number and trade dress will also remain unchanged for the present. First Data Bank and other pricing publications have been notified of Acorda's acquisition of this product. Please continue to process Zanaflex return goods under the existing Elan policies. To help expedite this transition, please process all Zanaflex return goods in-house ASAP through the following designated third-party return service provider. One Box Return Universal Solutions of New Jersey Munsonhurst Road Complex Franklin, NJ 07416 Phone: 1-800-321-7388   The company plans to  add a new patented dosage form to the Zanaflex line early next year. This addition, coupled with a new physician promotional  effort, is expected to significantly increase sales in this $280 million market. Acorda Therapeutics, a privately-held biotechnology company, develops therapies for spinal cord injury, multiple sclerosis and related conditions of the nervous system. Acorda also has several high potential therapies in development for the treatment of nervous system disorders. Should you have any questions about the product information or availability, please call the Acorda Customer Service Department at 1-866-351-0074. Medically related questions can be answered by the Medical Affairs department through one of the following methods. Toll Free Number: 1-800-367-5109 Fax: 510-595-8183 Direct Dial: 510-740-2420 e-mail: Acorda@medcomsol.com Thank you for your support, Sincerely, John Librie Executive Director, Marketing and Commercialization Acorda Therapeutics, Inc. Back to Previous Page ©2000 RPhLink.com The Pharmaceutical Care Network!     TaroPharma 10/10/2004 Lustra and Lustra-AF (hydroquinone USP 4%) Added to the TaroPharma Portfolio of Dermatology Products From: TaroPharma TaroPharma, a division of Taro Pharmaceuticals U.S.A., Inc. announces on July 29, 2004 the addition of two exceptional prescription products for the gradual treatment of ultraviolet light-induced dyschromia and discoloration resulting form the use of oral contraceptives, pregnancy, hormone replacement therapy, or skin trauma. Lustra and Lustra-AF were formerly marketed by Medicis Pharmaceutical Corp. Two of the leading products in their class, they have become a foremost choice of dermatologists for women with melasma, post-inflammatory hyperpigmentation and other forms of dyschromia. Incorporating a steroid-free antioxidant formulation platform, Lustra and Lustra-AF provide the flexibility or prescribing either a single entity hydroquinone or a combination with sunscreens to help prevent further sun-induced discoloration. During the ensuing transition from Medicis, NDC numbers will remain the same until inventory is depleted. Orders will be accepted and filled by Taro Pharma. Lustra (hydroquinone USP 4%)       NDC #99207-254-02 Lustra-A-F (hydroquinone USP 4%)   NDC #99207-256-02 Lustra-A-F contains the sunscreen Parsol 1789 (avobenzone) and octyl methoxycinnamate for UVA and UVB protection (SPF 20). Combining the sunscreens with the active ingredient helps assure patient compliance to sun protection steps necessary with the use of hydroquinone. Lustra contains no sunscreen protection. Since UV exposure stimulates melanogenesis faster than hydroquinone inhibits it, patients on Lustra therapy should use a broad-spectrum sunscreen (SPF 15 or greater). Occasional cutaneous hypersensitivity may occur with hydroquinone therapy. Hydroquinone may cause unwanted effects if not used as directed. Not intended to prevent sunburn. Warning: Contains sodium metabisulfite, a sulfite which may cause serious allergic reactions (e.g. hives, itching, wheezing, anaphylaxis, severe asthma attack) in certain susceptible persons. Please see full prescribing information on the back of this letter. The TaroPharma Sales Force will be supplying samples, patient literature and educational materials to support Lustra and Lustra-A-F. Stock up now on the renewed selling effort on these two outstanding products for UV induced dyschromia. Sincerely, Rachelle H. Goto, RPh Vice President Pharmacy Services